ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy

Das, Millie; Riess, Jonathan W.; Frankel, Paul; Schwartz, Erich; Bennis, Robyn; Hsieh, H. C.; Liu, Xiaohe; Ly, Janey C.; Zhou, Lisa; Nieva, Jorgé; Wakelee, Heather A.; Bruce, Richard H.

doi:10.1016/j.lungcan.2012.04.005

Cited by 51 publications

(44 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, ERCC1 ϩ CTC at primary diagnosis were superior in predicting the patient's prognosis than ERCC1 Ϫ CTC, by additionally constituting an independent predictor of a poor PFS. The prognostic relevance of ERCC1 ϩ CTC is principally in accordance with a recent very small pilot study analyzing 17 patients with metastatic non-small-cell lung cancer who were receiving platinum-based chemotherapy (36 ). Increased ERCC1 protein expression in the patient's CTC was associated with reduced PFS.…”

Section: Discussionsupporting

confidence: 68%

“…Increased ERCC1 protein expression in the patient's CTC was associated with reduced PFS. However, this pilot study did not resolve any association between CTC-derived ERCC1 expression and the patient's response to platinum-based chemotherapy (36 ). In this context, our findings support the idea that the additional evaluation of CTC-based ERCC1 transcripts in ovarian cancer patients significantly improves the prognostic impact and clinical utility of CTC as a blood-based biomarker for stratifying prognosis.…”

Section: Discussioncontrasting

confidence: 55%

See 1 more Smart Citation

ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance

et al. 2014

View full text Add to dashboard Cite

BACKGROUND Platinum resistance constitutes one of the most recognized clinical challenges for ovarian cancer. Notably, the detection of the primary tumor-based excision repair cross-complementation group 1 (ERCC1) protein by immunohistochemistry was recently shown to be inaccurate for the prediction of platinum resistance. On the basis of the previous finding that circulating tumor cells (CTC) in the blood of ovarian cancer patients are prognostically significant, and given our hypothesis that the negative prognostic impact of CTC may arise from a cellular phenotype associated with platinum resistance, we asked whether expression of the excision repair cross-complementation group 1 (ERCC1) gene in the form of the ERCC1 transcript in CTC may be a suitable blood-based biomarker for platinum resistance. METHODS The presence of CTC was analyzed by immunomagnetic CTC enrichment (n = 143 patients) targeting the epithelial epitopes epithelial cell adhesion molecule (EPCAM) (also known as GA733-2) and mucin 1, cell surface associated (MUC1), followed by multiplex reverse-transcription PCR to detect the transcripts EPCAM, MUC1, and mucin 16, cell surface associated (MUC16) (also known as CA125), including ERCC1 transcripts in a separate approach. ERCC1 expression in primary tumors was comparatively assessed by immunohistochemistry, using the antibody 8F1. RESULTS At primary diagnosis, the presence of CTC was observed in 14% of patients and constituted an independent predictor of overall survival (OS) (P = 0.041). ERCC1-positive CTC (ERCC1+CTC) were observed in 8% of patients and constituted an independent predictor, not only for OS but also for progression-free survival (PFS) (P = 0.026 and P = 0.009, respectively). More interestingly, we discovered the presence of ERCC1+CTC at primary diagnosis to be likewise an independent predictor of platinum resistance (P = 0.010), whereas ERCC1 expression in corresponding primary tumor tissue predicted neither platinum resistance nor prognosis. CONCLUSIONS The presence of ERCC1+CTC can serve as a blood-based diagnostic biomarker for predicting platinum resistance at primary diagnosis of ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussioncontrasting

confidence: 55%

ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, the emergence of new data highlighting the importance of (Das et al, 2012;Krivacic et al, 2004;Somlo et al, 2011) CytoTrack CK, CD45, DAPI Special glass disc scanned as it spins, clusters observed, 100 M cells/min (Hillig et al, 2015) In vivo Photoacoustic flow cytometry (PAFC)…”

Section: Vortex Sizementioning

confidence: 99%

Circulating tumor cell technologies

2016

View full text Add to dashboard Cite

Cancer CTC capture CTC clustersImmunoaffinity enrichment A B S T R A C TCirculating tumor cells, a component of the "liquid biopsy", hold great potential to transform the current landscape of cancer therapy. A key challenge to unlocking the clinical utility of CTCs lies in the ability to detect and isolate these rare cells using methods amenable to downstream characterization and other applications. In this review, we will provide an overview of current technologies used to detect and capture CTCs with brief insights into the workings of individual technologies. We focus on the strategies employed by different platforms and discuss the advantages of each. As our understanding of CTC biology matures, CTC technologies will need to evolve, and we discuss some of the present challenges facing the field in light of recent data encompassing epithelial-to-mesenchymal transition, tumor-initiating cells, and CTC clusters.

show abstract

“…It is believed that CTCs were vital to metastasis through settling and creating secondary lesions (9,10). To date, extensive studies reported that CTCs have closed relationship with characteristics in different kinds of cancer (11)(12)(13). However, research on CTCs from NPC is still lacking.…”

Section: Introductionmentioning

confidence: 99%

Distribution and clinical significance of circulating tumor cells in nasopharyngeal carcinoma

Lan

Deng

et al. 2016

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Nasopharyngeal carcinoma is one of the leading malignancies with obscure etiology. Circulating tumor cells have been showed to intimately correlate with characteristics in different kinds of cancer. But links between circulating tumor cells and nasopharyngeal carcinoma were still lacking. Therefore, we explored circulating tumor cells' distribution in nasopharyngeal carcinoma and their possible associations with nasopharyngeal carcinoma. Methods: Firstly, we found that the positive ratio of circulating tumor cells is extremely high in four stages of nasopharyngeal carcinoma. Meanwhile, positive ratios of mesenchymal circulating tumor cells were higher in early stages of nasopharyngeal carcinoma. Apart from epithelial circulating tumor cells, total, hybrid and mesenchymal circulating tumor cells were correlated with nasopharyngeal carcinoma clinical stage. Results: Our results showed that hybrid and mesenchymal circulating tumor cells were associated with nasopharyngeal carcinoma metastasis (both distant and lymph node) and smoking. Meanwhile, hybrid circulating tumor cells expressed the highest Epstein-Barr virus proteins and deoxyribonucleic acid in three types of circulating tumor cells. Moreover, we found that Epstein-Barr virus proteins viral-caspid antigen-immunoglobulin A (VCA/IgA) and early antigen-immunoglobulin A (EA/IgA), but not Epstein-Barr virus-deoxyribonucleic acid, had a closed association with nasopharyngeal carcinoma metastasis. However, Epstein-Barr virus hallmarks failed to associate with other nasopharyngeal carcinoma characteristics. Furthermore, we confirmed that matrix metalloproteinase 9 existed in circulating tumor cells and expressed most in mesenchymal circulating tumor cells. In addition, matrix metalloproteinase 9-expressed extent in hybrid circulating tumor cells is somewhat different from epithelial and mesenchymal circulating tumor cells in matrix metalloproteinase 9-positive circulating tumor cells. Nevertheless, matrix metalloproteinase 9 had no relationship with other nasopharyngeal carcinoma characteristics. Finally, our results showed that circulating tumor cells were decreased in patients after therapies. carcinoma metastasis. Of note, decreased circulating tumor cells indicated a favorable curative effect in nasopharyngeal carcinoma patients.

show abstract

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy

Cited by 51 publications

References 32 publications

ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance

ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance

Circulating tumor cell technologies

Distribution and clinical significance of circulating tumor cells in nasopharyngeal carcinoma

Contact Info

Product

Resources

About